

PRESS RELEASE 22 September 2009

Kirkstall and Agenda 1 are selected as finalists for the 2009 CPhI/ICSE Innovation award – Madrid 13-15 October 2009

Kirkstall Limited, the Sheffield-based developer of *in vitro* systems for testing the safety and efficacy of compounds are pleased to announce that Kirkstall's **Quasi-Vivo**TM *in vitro* compound testing system and Agenda 1's **SOLENT**TM solubilizing screen have been jointly selected by the CPhI judges as a finalist for the Innovation Award 2009.

In collaboration with Kirkstall's CRO partners, Agenda 1 analytical, the team will present at the CPhI in Madrid on 13th October. The presentation entitled "Reducing animal testing and speeding up drug development" will showcase both Kirkstall and Agenda 1's platform technologies. The presentation will illustrate how the two companies have technologies that can dovetail together to provide a unique platform for streamlining drug discovery and development.

Kirkstall's CEO, Dr Malcolm Wilkinson, welcomed the news and said "This is great news for Kirkstall. It recognises the potential impact of our technology and will give us an outstanding opportunity to showcase it to the many thousands of delegates who will be visiting CPhI"

The winners of this prestigious award will be announced at the CPhI on the 13th October.

[Visit us at stand 8NE11](#)

